PDF(Pubmed)
Abstract：
Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is an aggressive hematologic malignancy. T-ALL patients who are treated with chemotherapeutic drugs frequently relapse and become drug resistant. Therefore, antibody-based therapy is promising for T-ALL treatment. To successfully develop an antibody-based therapy for T-ALL, antibodies that induce death in malignant T cells but not in nonmalignant T cells are required to avoid the induction of secondary T-cell immunodeficiency. In this review, CD99 tumor associated antigen, which is highly expressed on malignant T cells and lowly expressed on nonmalignant T cells, is proposed to be a potential target for antibody therapy of T-ALL. Since certain clones of anti-CD99 mAbs induce apoptosis only in malignant T cells, these anti-CD99 mAbs might be a promising antibody drug for the treatment of T-ALL with high efficiency and low adverse effects. Moreover, over the past 25 years, many clones of anti-CD99 mAbs have been studied for their direct effects on T-ALL. These outcomes are gathered here.
摘要：
单克隆抗体（mAb）是几种癌症类型的靶向免疫治疗的有效药物。然而,到目前为止,尚未成功开发出针对某些类型癌症的抗体，包括T细胞急性淋巴细胞白血病（T-ALL）。T-ALL是一种侵袭性血液系统恶性肿瘤。用化疗药物治疗的T-ALL患者经常复发并变得耐药。因此,基于抗体的治疗有望用于T-ALL治疗.为了成功开发基于抗体的T-ALL疗法，诱导恶性T细胞死亡而非非恶性T细胞死亡的抗体是避免继发性T细胞免疫缺陷诱导所必需的.在这次审查中,CD99肿瘤相关抗原，在恶性T细胞上高表达，在非恶性T细胞上低表达，被认为是T-ALL抗体治疗的潜在靶点。由于抗CD99mAb的某些克隆仅在恶性T细胞中诱导凋亡，这些抗CD99mAb可能是治疗T-ALL的一种有前景的抗体药物,具有高效率和低副作用.此外，在过去的25年里，已经研究了抗CD99mAb的许多克隆对T-ALL的直接作用。这些结果都集中在这里。
